GR980300029T1 - Orphan receptor - Google Patents

Orphan receptor

Info

Publication number
GR980300029T1
GR980300029T1 GR980300029T GR980300029T GR980300029T1 GR 980300029 T1 GR980300029 T1 GR 980300029T1 GR 980300029 T GR980300029 T GR 980300029T GR 980300029 T GR980300029 T GR 980300029T GR 980300029 T1 GR980300029 T1 GR 980300029T1
Authority
GR
Greece
Prior art keywords
amino acid
acid sequence
receptor
relates
disorders
Prior art date
Application number
GR980300029T
Other languages
English (en)
Inventor
George G J M Kuiper
Eva Enmark
Jan-Ake Gustafsson
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR980300029(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Application filed by Karobio Ab filed Critical Karobio Ab
Publication of GR980300029T1 publication Critical patent/GR980300029T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR980300029T 1995-09-08 1998-04-30 Orphan receptor GR980300029T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor
PCT/EP1996/003933 WO1997009348A2 (en) 1995-09-08 1996-09-09 Orphan receptor

Publications (1)

Publication Number Publication Date
GR980300029T1 true GR980300029T1 (en) 1998-04-30

Family

ID=27451339

Family Applications (2)

Application Number Title Priority Date Filing Date
GR980300029T GR980300029T1 (en) 1995-09-08 1998-04-30 Orphan receptor
GR990402716T GR3031618T3 (en) 1995-09-08 1999-10-26 Orphan receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
GR990402716T GR3031618T3 (en) 1995-09-08 1999-10-26 Orphan receptor

Country Status (12)

Country Link
US (2) US5958710A (el)
EP (2) EP0792292B2 (el)
JP (4) JP3131649B2 (el)
KR (1) KR100263137B1 (el)
AT (1) ATE183516T1 (el)
AU (1) AU715528B2 (el)
CA (1) CA2201098C (el)
DE (2) DE69603827T3 (el)
DK (1) DK0792292T4 (el)
ES (1) ES2135249T5 (el)
GR (2) GR980300029T1 (el)
WO (1) WO1997009348A2 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200423C (en) 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
EP0866127A3 (en) * 1997-03-17 1999-12-22 Smithkline Beecham Plc HE8AN36, a steroid hormone receptor homolog
AU735703B2 (en) * 1997-06-10 2001-07-12 Karo Bio Ab Estrogen receptor ligands
US7157568B1 (en) * 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
ES2268789T3 (es) * 1997-09-08 2007-03-16 MERCK & CO., INC. Receptor de estrogeno.
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
DE19839115A1 (de) * 1998-08-27 2000-03-09 Ihf Inst Fuer Hormon Und Fortp Klonierung und Expression von Rinder Estrogenrezeptor-beta
EP1400810A3 (en) * 1999-04-09 2005-03-02 Karo Bio Ab Estrogen receptors and bone disease
AU4546900A (en) * 1999-04-09 2000-11-14 Karo Bio Ab Estrogen receptors and bone
AU2002247702A1 (en) * 2001-02-09 2002-08-28 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
WO2002070697A1 (en) * 2001-03-02 2002-09-12 Lion Bioscience Ag Mammalian nuclear receptor l67 and methods of use
EP1411922A1 (en) 2001-07-31 2004-04-28 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
ATE362471T1 (de) 2001-11-19 2007-06-15 Lilly Co Eli Substituierte benzopyrane als selektive agonisten am östrogenrezeptor-beta
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
WO2003050133A1 (en) * 2001-12-07 2003-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor beta expression
CA2365811A1 (en) * 2001-12-21 2003-06-21 Institut De Cardiologie A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
RU2348653C2 (ru) 2003-02-21 2009-03-10 Дау Глобал Текнолоджиз Инк. Способ гомо- или сополимеризации сопряженных олефинов
WO2004094401A1 (en) 2003-04-21 2004-11-04 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
CN100374444C (zh) 2003-04-21 2008-03-12 伊莱利利公司 作为选择性β-雌激素受体激动剂的取代的苯并吡喃化合物
KR20060066070A (ko) 2003-07-28 2006-06-15 스미스클라인 비참 코포레이션 에스트로겐 수용체의 조절제로서의 시클로알킬리덴 화합물
EP1709443A2 (en) * 2003-12-18 2006-10-11 Procognia, Ltd. Method for analyzing a glycomolecule
KR20070061536A (ko) 2004-09-07 2007-06-13 와이어쓰 ６Ｈ-[１]벤조피라노[４,３-ｂ]퀴놀린 및 에스트로겐제제로서의 이의 용도
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5602009A (en) * 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
EP0463081B1 (en) * 1989-03-17 1998-05-20 The Salk Institute For Biological Studies Hormone response element compositions and assay
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
WO1995013373A1 (en) * 1993-11-10 1995-05-18 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor

Also Published As

Publication number Publication date
CA2201098C (en) 2001-03-27
EP0792292A2 (en) 1997-09-03
ES2135249T3 (es) 1999-10-16
JP3131649B2 (ja) 2001-02-05
AU715528B2 (en) 2000-02-03
KR100263137B1 (ko) 2000-08-01
WO1997009348A2 (en) 1997-03-13
US20030113803A1 (en) 2003-06-19
WO1997009348A3 (en) 1997-04-24
JP2005204666A (ja) 2005-08-04
EP0792292B2 (en) 2009-04-15
DK0792292T3 (da) 2000-02-07
US7132261B2 (en) 2006-11-07
DE69603827D1 (de) 1999-09-23
DE792292T1 (de) 1998-09-03
DE69603827T2 (de) 2000-02-24
EP0935000A2 (en) 1999-08-11
EP0792292B1 (en) 1999-08-18
GR3031618T3 (en) 2000-01-31
CA2201098A1 (en) 1997-03-13
ES2135249T5 (es) 2009-09-10
DK0792292T4 (da) 2009-07-20
JPH11502417A (ja) 1999-03-02
US5958710A (en) 1999-09-28
JP2002010788A (ja) 2002-01-15
EP0935000A3 (en) 1999-09-08
AU6988096A (en) 1997-03-27
ATE183516T1 (de) 1999-09-15
JP2005204667A (ja) 2005-08-04
DE69603827T3 (de) 2009-11-05

Similar Documents

Publication Publication Date Title
GR980300029T1 (en) Orphan receptor
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
MX9700553A (es) Anticuerpos que activan un receptor de eritropoyetina.
BG103436A (en) Conjugates applicable in the treatment of the prostate gland cancer
BR9710636A (pt) Análogo de somatostatina ciclizada da espinha dorsal, uso do mesmo, composição farmacêutica,e , processo de tratamento de distúrbios endócrinos, neoplasmas ou distúrbios metabólicos.
AU6045398A (en) Androgen synthesis inhibitors
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
MXPA00012586A (es) Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
IL142132A0 (en) Methods and compositions for treating receptor mediated diseases
EP1955700A3 (en) Therapeutic treatment of androgen receptor driven conditions
PL328858A1 (en) Immunogenous peptides
MX9708401A (es) Genes reguladores de la cromatina.
AP9801269A0 (en) Prostaglandin agonists.
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
WO2005027833A3 (en) Compound and method for treating androgen-independent prostate cancer
BG103472A (en) Polypeptides encoded by a human lipase-like gene, compositions and methods
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
IL132094A0 (en) Methods and compositions for treatment of ovarian cancer
CA2340475A1 (en) Orphan receptor
Miller et al. Elevated intrinsic reactivity of seryl hydroxyl groups within the linear peptide triads His-Xaa-Ser or Ser-Xaa-His
AU1719500A (en) Method for augmenting the inotropic effects of beta-adrenergic agonists using pyruvate therapy
EP1077892A4 (en) METHOD AND COMPOSITION FOR IMPROVING THE UNIFORMITY OF APPLICATION OF A SIZE
Neuhaus Which test for common bile duct stones? Endoscopic retrograde cholangiopancreatography
IL122316A0 (en) Melatonin agonists for treating benign prostatic hyperplasia